Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia.

Trial Profile

Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 12 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top